Absence or presence of the SRY gene as an indication for biological sex
To promote fairness in women’s sports, the World Athletics Federation has implemented a policy requiring genetic testing for the presence or absence of the SRY gene as an indicator of biological sex. Beginning September 1, 2025, all athletes intending to compete in the female category at the World Championships must undergo a one-time SRY gene test.
Amplexa Genetics has developed a molecular test for the SRY gene. The test is intended for elite athletes wishing to compete in national and international competitions. The test is based on a quantitative Polymerase Chain Reaction (qPCR) of the SRY gene (Sex determining Region Y), a test which has a very high specificity and sensitivity.
The report will be giving the status on the absence or presence of the SRY gene as an indication for biological sex and the result is solely intended for classification into a sporting category.
In case a female athlete shows the presence of the SRY gene we recommend clinical genetic counselling. Amplexa Genetics can deliver clinical genetic counselling and molecular genetic follow up analyses for the presence of a Y-chromosome or sex chromosome ploidy. We also have collaboration with hospital who can deliver the biochemical follow up analyses and clinical assessment for EG insensitivity syndrome.
Analysis reports are delivered anonymously directly to the athlete through a secure e-mail system. The report is delivered as a pdf document with a digital document verification system. The digital document verification system ensures that the results can’t be modified in the document.